Compare Eli Lilly And Co (LLY) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs AT&T Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while AT&T Inc. trades at $22.18 (market cap $170.42B). The key difference: Eli Lilly And Co is far larger — about 6.1× AT&T Inc.'s market cap, and AT&T Inc. pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and AT&T Inc. for 118 Days on average.
| LLY | T | |
|---|---|---|
Market Cap | $1.04T | $170.42B |
Volume | 3,064,878 | 50,780,036 |
Sector | Health | Media |
52-Week High | $1.28K | $29.10 |
52-Week Low | $799.57 | $20.49 |
Typical Hold Time | 93 Days | 118 Days |
Enterprise Value | $1.09T | $315.74B |
Dividend Yield | 0.59% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
AT&T (T) trades at $24.885, up 1.68% over 24 hours, with a bullish technical signal despite mixed moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Fundamentals show solid profitability with a 16.94% net margin and attractive valuation metrics, including a P/E of 8.21. Recent news highlights a $3 billion fiber deal with Corning and joint venture developments with telecom peers to expand coverage.
The outlook for AT&T is cautiously optimistic, supported by earnings momentum and strategic investments in fiber and AI infrastructure. Key risks include high debt levels, competitive pressures, and potential dividend sustainability concerns. Analyst consensus leans neutral with a $27.50 price target, suggesting moderate upside from current levels amid balanced sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
